Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1520 : JHOC-5  update : 2024/11/11
CommentHuman cell line derived from ovarian clear cell adenocarcinoma. Said CA125 and CA72-4 producing. Application consideration
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
Remarks
approver's address
×
English
Address
Contact Us
cellbank.brc@riken.jp
RIKEN, BioResource Research Center
Cell Engineering Division
Dr.ISHIKAWA Hiroshi (Cell Bank)
Fax. +81-29-836-9130
Order Form Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Ishikawa, Hiroshi
Originator Ishikawa, H. & Yasuda, M.
Year of deposit 1999
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 54 years
Tissue ovary
Disease name Clear cell carcinoma of ovary
Metastatic ability Yes
Metastatic tissue lymph node
Classification cancer
Year of origin 1998
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_4640
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium DMEM/HamF12 + 10% FBS + 0.1mM NEAA
Antibiotics Free
Passage method (0.05% Trypsin + 0.02% EDTA) or (0.25% Trypsin + 0.04% EDTA)
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma/Acholeplasma (-)
Isozyme LD, NP
Chromosome mode 56-67(50) : /61(7),62(10),63(20),67(1)/
STR(human) OK
Images
deposit info
lot info
Reference information Reference 1
User's Publication 45


To topTop
Reference
2405  Yamada K, Tachibana T, Hashimoto H, Suzuki K, Yanagida S, Endoh H, Kimura E, Yasuda M, Tanaka T, Ishikawa H  Establishment and characterization of cell lines derived from serous adenocarcinoma (JHOS-2) and clear cell adenocarcinoma (JHOC-5, JHOC-6) of human ovary.  Hum Cell  1999  12:131-8  PubMed ID: 10695020  

To topTop
User's Publication
21561  Suzuki H, Nagase S, Saito C, Takatsuka A, Nagata M, Honda K, Kaneda Y, Nishiya Y, Honda T, Ishizaka T, Nakamura K, Nakada T, Abe Y, Agatsuma T.  Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, is Efficacious in Human Ovarian and Kidney Cancer Models.  Mol Cancer Ther  2024    PubMed ID: 38205802   DOI: 10.1158/1535-7163.MCT-23-0287
21814  Tsunematsu R, Murai A, Mizue Y, Kubo T, Mariya T, Morita R, Murata K, Kanaseki T, Tsukahara T, Hirohashi Y, Saito T, Torigoe T.  Restoration of ARID1A Protein in ARID1A-deficient Clear Cell Carcinoma of the Ovary Attenuates Reactivity to Cytotoxic T Lymphocytes.  Cancer Genomics Proteomics  2024  21(4):414-420  PubMed ID: 38944423   DOI: 10.21873/cgp.20460
21271  Ferrari AJ, Rawat P, Rendulich HS, Annapragada AV, Kinose Y, Zhang X, Devins K, Budina A, Scharpf RB, Mitchell MA, Tanyi JL, Morgan MA, Schwartz LE, Soong TR, Velculescu VE, Drapkin R.  H2Bub1 loss is an early contributor to clear cell ovarian cancer progression.  JCI Insight  2023  8(12)  PubMed ID: 37345659   DOI: 10.1172/jci.insight.164995
21399  Akashi H, Yachida N, Ueda H, Yamaguchi M, Yamawaki K, Tamura R, Suda K, Ishiguro T, Adachi S, Nagase Y, Ueda Y, Ueda M, Abiko K, Kagabu M, Baba T, Nakaoka H, Enomoto T, Murai J, Yoshihara K.  SLFN11 is a BRCA independent biomarker for the response to platinum-based chemotherapy in high-grade serous ovarian cancer and clear cell ovarian carcinoma.  Mol Cancer Ther  2023    PubMed ID: 37717249   DOI: 10.1158/1535-7163.MCT-23-0257
21429  Thorel L, Morice PM, Paysant H, Florent R, Babin G, Thomine C, Perréard M, Abeilard E, Giffard F, Brotin E, Denoyelle C, Villenet C, Sebda S, Briand M, Joly F, Dolivet E, Goux D, Blanc-Fournier C, Jeanne C, Villedieu M, Meryet-Figuiere M, Figeac M, Poulain L, Weiswald LB.  Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.  J Exp Clin Cancer Res  2023  42(1):260  PubMed ID: 37803448   DOI: 10.1186/s13046-023-02809-8
21483  Tsuchimochi S, Wada-Hiraike O, Urano Y, Kukita A, Yamaguchi K, Honjo H, Taguchi A, Tanikawa M, Sone K, Mori-Uchino M, Tsuruga T, Oda K, Osuga Y.  Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma.  Sci Rep  2023  13(1):20292  PubMed ID: 37985723   DOI: 10.1038/s41598-023-47637-0
20728  Mehner C, Hockla A, Coban M, Madden B, Estrada R, Radisky DC, Radisky ES.  Activity-based protein profiling reveals active serine proteases that drive malignancy of human ovarian clear cell carcinoma.  J Biol Chem  2022  102146  PubMed ID: 35716777   DOI: 10.1016/j.jbc.2022.102146
20211  Oyama Y, Shigeta S, Tokunaga H, Tsuji K, Ishibashi M, Shibuya Y, Shimada M, Yasuda J, Yaegashi N.  CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.  PLoS One  2021  16(6):e0251079  PubMed ID: 34161330   DOI: 10.1371/journal.pone.0251079
14932  Ota Y, Koizume S, Nakamura Y, Yoshihara M, Takahashi T, Sato S, Myoba S, Ohtake N, Kato H, Yokose T, Miyagi E, Miyagi Y.  Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix  Oncol Rep  2021  45(3):1023-1032  PubMed ID: 33650653   DOI: 10.3892/or.2021.7944
17036  Wu S, Fukumoto T, Lin J, Nacarelli T, Wang Y, Ong D, Liu H, Fatkhutdinov N, Zundell JA, Karakashev S, Zhou W, Schwartz LE, Tang HY, Drapkin R, Liu Q, Huntsman DG, Kossenkov AV, Speicher DW, Schug ZT, Van Dang C, Zhang R.  Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma  Nat Cancer   2021  2(2):189-200  PubMed ID: 34085048   DOI: 10.1038/s43018-020-00160-x
9662  Ji JX, Cochrane DR, Tessier-Cloutier B, Chen SY, Ho G, Pathak KV, Alcazar IN, Farnell D, Leung S, Cheng A, Chow C, Colborne S, Negri GL, Kommoss F, Karnezis A, Morin GB, McAlpine JN, Gilks CB, Weissman BE, Trent JM, Hoang L, Pirrotte P, Wang Y, Huntsman DG.  Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type  Clin Cancer Res  2020  26(16):4402-4413  PubMed ID: 32409304   DOI: 10.1158/1078-0432.CCR-19-1905
13109  De Haven Brandon A, Box G, Hallsworth A, Court W, Matthews N, Herodek B, Arteagabeitia AB, Valenti M, Kirkin V.  Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.  Sci Rep  2020    PubMed ID: 32612269   DOI: 10.1038/s41598-020-67533-1
13249  Minagawa Y, Ishino K, Wada R, Kudo M, Naito Z, Takeshita T, Ohashi R.  High Expression of p21 as a Potential Therapeutic Target in Ovarian Clear-cell Carcinoma.  Anticancer Res  2020    PubMed ID: 32988887   DOI: 10.21873/anticanres.14576
14802  Shen YA, Hong J, Asaka R, Asaka S, Hsu FC, Suryo Rahmanto Y, Jung JG, Chen YW, Yen TT, Tomaszewski A, Zhang C, Attarwala N, DeMarzo AM, Davidson B, Chuang CM, Chen X, Gaillard S, Le A, Shih IM, Wang TL.  Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers  Cancer Res  2020  80(20):4514-4526  PubMed ID: 32859605   DOI: 10.1158/0008-5472.CAN-19-3971
14853  Arildsen NS, Hedenfalk I.  Simvastatin is a potential candidate drug in ovarian clear cell carcinomas  Oncotarget  2020  11(40):3660-3674  PubMed ID: 33088426   DOI: 10.18632/oncotarget.27747
11322  Kato N, Sato Y, Kamataki A, Fukase M, Uchigasaki S, Kurose A.  PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.  Hum. Pathol.  2019    PubMed ID: 30496799   DOI: 10.1016/j.humpath.2018.11.013
11632  Caumanns JJ, van Wijngaarden A, Kol A, Meersma GJ, Jalving M, Bernards R, van der Zee AGJ, Wisman GBA, de Jong S.  Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.  Cancer Lett.  2019    PubMed ID: 31319139   DOI: 10.1016/j.canlet.2019.07.004
11966  Sahin ID, Jönsson JM, Hedenfalk I.  Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer.  Oncotarget  2019    PubMed ID: 31857852   DOI: 10.18632/oncotarget.27363
12482  Kim HJ, Lee S, Oh YS, Chang HK, Kim YS, Hong SH, Kim JY, Park YW, Lee SJ, Song SW, Kim JJ, Heo K.  Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression  Front Oncol  2019  9:571  PubMed ID: 31355133   DOI: 10.3389/fonc.2019.00571
14809  Yasuto Kinose, Dorothy Hallberg, Kai Doberstein, Gordon Mills, Tan Ince, Victor Velculescu, Fiona Simpkins, Ronny Drapkin  Abstract 1065: Comprehensive molecular and experimental characterization of ovarian clear cell carcinoma cell lines forin vivodrug development  Tumor Biology  2019      DOI: 10.1158/1538-7445.am2019-1065
11075  Berns K, Caumanns JJ, Hijmans EM, Gennissen AMC, Severson TM, Evers B, Wisman GBA, Jan Meersma G, Lieftink C, Beijersbergen RL, Itamochi H, van der Zee AGJ, de Jong S, Bernards R.  ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.  Oncogene  2018  37(33):4611-4625  PubMed ID: 29760405   DOI: 10.1038/s41388-018-0300-6
11109  Le Naour A, Mevel R, Thibault B, Courtais E, Chantalat E, Delord JP, Couderc B, Guillermet-Guibert J, Martinez A.  Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.  Oncotarget  2018  9(43):27220-27232  PubMed ID: 29930760   DOI: 10.18632/oncotarget.25513
10087  Sato M, Kawana K, Adachi K, Fujimoto A, Taguchi A, Fujikawa T, Yoshida M, Nakamura H, Nishida H, Inoue T, Ogishima J, Eguchi S, Yamashita A, Tomio K, Arimoto T, Wada-Hiraike O, Oda K, Nagamatsu T, Osuga Y, Fujii T.  Low uptake of fluorodeoxyglucose in positron emission tomography/computed tomography in ovarian clear cell carcinoma may reflect glutaminolysis of its cancer stem cell-like properties.  Oncol. Rep.  2017  37:1883-1888  PubMed ID: 28112360   DOI: 10.3892/or.2017.5398
10161  Sato M, Kawana K, Adachi K, Fujimoto A, Yoshida M, Nakamura H, Nishida H, Inoue T, Taguchi A, Ogishima J, Eguchi S, Yamashita A, Tomio K, Wada-Hiraike O, Oda K, Nagamatsu T, Osuga Y, Fujii T.  Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro.  Int. J. Oncol.  2017  50:1431-1438  PubMed ID: 28259988   DOI: 10.3892/ijo.2017.3891
9659  Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R Grassian, Igor Feldman, Sarah K Knutson, Kristy Kuplast-Barr, Maria Roche, John Campbell, Peter Ho, Robert A Copeland, Richard Chesworth, Jesse J Smith, Heike Keilhack, Scott A Ribich  Selective Killing of SMARCA2- And SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models  Mol Cancer Ther   2017  16(5):850-860  PubMed ID: 28292935   DOI: 10.1158/1535-7163.MCT-16-0678
7404  Yanaihara N, Hirata Y, Yamaguchi N, Noguchi Y, Saito M, Nagata C, Takakura S, Yamada K, Okamoto A.  Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.  Mol. Carcinog.  2016  55:832-41  PubMed ID: 25856562   DOI: 10.1002/mc.22325
9636  Nozomu Yanaihara, Yukiko Noguchi 1, Misato Saito 1, Masataka Takenaka 1, Satoshi Takakura 2, Kyosuke Yamada 1, Aikou Okamoto 1  MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma  PLoS One  2016  11(9):e0162584  PubMed ID: 27612152   DOI: 10.1371/journal.pone.0162584
12611  Kato N, Kurotaki H, Uchigasaki S, Fukase M, Kurose A.  Ovarian clear cell carcinoma with plasma cell-rich inflammatory stroma: a clear cell carcinoma subgroup with distinct clinicopathological features  Histopathology  2016  68(4):588-95  PubMed ID: 26211695   DOI: 10.1111/his.12783
7410  Takenaka M, Saito M, Iwakawa R, Yanaihara N, Saito M, Kato M, Ichikawa H, Shibata T, Yokota J, Okamoto A, Kohno T.  Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.  Int. J. Oncol.  2015  46:2389-98  PubMed ID: 25846456   DOI: 10.3892/ijo.2015.2951
14315  Davis SJ, Sheppard KE, Anglesio MS, George J, Traficante N, Fereday S, Intermaggio MP, Menon U, Gentry-Maharaj A, Lubinski J, Gronwald J, Pearce CL, Pike MC, Wu A, Kommoss S, Pfisterer J, du Bois A, Hilpert F, Ramus SJ, Bowtell DD, Huntsman DG, Pearson RB, Simpson KJ, Campbell IG, Gorringe KL.  Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition  Mol Cancer Ther  2015  14(6):1495-503  PubMed ID: 25852062   DOI: 10.1158/1535-7163.MCT-15-0039
14956  Takata A, Terauchi M, Hiramitsu S, Uno M, Wakana K, Kubota T.  Dkk-3 induces apoptosis through mitochondrial and Fas death receptor pathways in human mucinous ovarian cancer cells  Int J Gynecol Cancer  2015  25(3):372-9  PubMed ID: 25514350   DOI: 10.1097/IGC.0000000000000340
15031  Takaya A, Peng WX, Ishino K, Kudo M, Yamamoto T, Wada R, Takeshita T, Naito Z.  Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma  Int J Oncol  2015  46(4):1573-81  PubMed ID: 25633807   DOI: 10.3892/ijo.2015.2858
15235  Amano Y, Mandai M, Yamaguchi K, Matsumura N, Kharma B, Baba T, Abiko K, Hamanishi J, Yoshioka Y, Konishi I.  Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival  Oncotarget  2015  6(28):26002-17  PubMed ID: 26318292   DOI: 10.18632/oncotarget.4692
9634  Kanako Shinjo, Yoriko Yamashita, Eiko Yamamoto, Shinya Akatsuka, Nozomi Uno, Akihiro Kamiya, Kaoru Niimi, Yuka Sakaguchi, Tetsuro Nagasaka, Takashi Takahashi, Kiyosumi Shibata, Hiroaki Kajiyama, Fumitaka Kikkawa, Shinya Toyokuni  Expression of Chromobox Homolog 7 (CBX7) Is Associated With Poor Prognosis in Ovarian Clear Cell Adenocarcinoma via TRAIL-induced Apoptotic Pathway Regulation  Int J Cancer  2014  135(2):308-18  PubMed ID: 24375438   DOI: 10.1002/ijc.28692
13692  Uno M, Saitoh Y, Mochida K, Tsuruyama E, Kiyono T, Imoto I, Inazawa J, Yuasa Y, Kubota T, Yamaoka S.  NF-κB inducing kinase, a central signaling component of the non-canonical pathway of NF-κB, contributes to ovarian cancer progression  PLoS One  2014  9(2):e88347.  PubMed ID: 24533079   DOI: 10.1371/journal.pone.0088347
14316  Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.  A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation  BMC Cancer  2014  14:120  PubMed ID: 24559118   DOI: 10.1186/1471-2407-14-120
17115  Hirata Y, Murai N, Yanaihara N, Saito M, Saito M, Urashima M, Murakami Y, Matsufuji S, Okamoto A.  MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma  BMC Cancer  2014  14:799  PubMed ID: 25366985   DOI: 10.1186/1471-2407-14-799
9635  Yoriko Yamashita, Shinya Akatsuka, Kanako Shinjo, Yasushi Yatabe, Hiroharu Kobayashi, Hiroshi Seko, Hiroaki Kajiyama, Fumitaka Kikkawa, Takashi Takahashi, Shinya Toyokuni  Met Is the Most Frequently Amplified Gene in Endometriosis-Associated Ovarian Clear Cell Adenocarcinoma and Correlates With Worsened Prognosis  PLoS One  2013  8(3):e57724  PubMed ID: 23469222   DOI: 10.1371/journal.pone.0057724
9669  Ikue Nakayama, Masahiko Shibazaki, Akiko Yashima-Abo, Fumiharu Miura, Toru Sugiyama, Tomoyuki Masuda, Chihaya Maesawa  Loss of HOXD10 Expression Induced by Upregulation of miR-10b Accelerates the Migration and Invasion Activities of Ovarian Cancer Cells  Int J Oncol  2013  43(1):63-71  PubMed ID: 23670532   DOI: 10.3892/ijo.2013.1935
9657  Nozomu Yanaihara, Michael S Anglesio, Kazunori Ochiai, Yukihiro Hirata, Misato Saito, Chie Nagata, Yasushi Iida, Satoshi Takakura, Kyosuke Yamada, Tadao Tanaka, Aikou Okamoto  Cytokine Gene Expression Signature in Ovarian Clear Cell Carcinoma  Int J Oncol   2012  41(3):1094-100  PubMed ID: 22751940   DOI: 10.3892/ijo.2012.1533
8331  Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Miyazaki K.  Loss of MKK4 expression in ovarian cancer: a potential role for the epithelial to mesenchymal transition.  Int. J. Cancer  2011  128:94-104  PubMed ID: 20309881   DOI: 10.1002/ijc.25332
6298  Izutsu N, Maesawa C, Shibazaki M, Oikawa H, Shoji T, Sugiyama T, Masuda T.  Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.  Int J Oncol  2008  32(6):1227-35  PubMed ID: 18497984   DOI: 10.3892/ijo_32_6_1227
15560  Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, Sasano H, Yaegashi N.  Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.  Cancer Sci  2008  99:2365-72  PubMed ID: 19032364   DOI: 10.1111/j.1349-7006.2008.00988.x
2934  Akahira, Jun-ichi, Sugihashi, Youko, Suzuki, Takashi, Ito, Kiyoshi, Niikura, Hitoshi, Moriya, Takuya, Nitta, Makoto, Okamura, Hitoshi, Inoue, Satoshi, Sasano, Hironobu, Okamura, Kunihiro, Yaegashi, Nobuo  Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation.  Clin Cancer Res  2004  10:2687-93  PubMed ID: 15102672   DOI: 10.1158/1078-0432.ccr-03-0510
3796  Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y.  Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.  Int J Cancer  2003  107(1):53-9  PubMed ID: 12925956   DOI: 10.1002/ijc.11348


Back Back Return Top Page